Indication

Lymphangioleiomyomatosis

Lymphangioleiomyomatosis is a rare, progressive multisystem disease characterized by the abnormal clonal proliferation of atypical smooth muscle-like cells throughout the pulmonary parenchyma, axial lymphatics, and vascular structures. Read more about Lymphangioleiomyomatosis

26 drugs 22 manufacturers

Advertisement

Drugs that treat it

Common Lymphangioleiomyomatosis therapies.

Showing 10–18 of 26 drugs

SIROLIMUS

PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
VISTAPHARM

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
Amneal Pharmaceuticals

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
GREENSTONE LLC.

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
Major Pharamceuticals

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
NORTHSTAR RX LL

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
CAMBER PHARMACE

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
AVPAK

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
APOTEX CORP

SIROLIMUS

IMMUNOSUPPRESSANTS - MTOR INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+1
ASCEND LABORATO
Filter & compare in the drug finder →Opens the drug finder with Lymphangioleiomyomatosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Lymphangioleiomyomatosis.

Lymphangioleiomyomatosis is a rare, progressive multisystem disease characterized by the abnormal clonal proliferation of atypical smooth muscle-like cells throughout the pulmonary parenchyma, axial lymphatics, and vascular structures.

It primarily affects women of reproductive age and occurs either sporadically or in association with tuberous sclerosis complex.

Pathophysiologically driven by hyperactivation of the mechanistic target of rapamycin signaling pathway, the condition leads to diffuse cystic lung destruction, recurrent spontaneous pneumothoraces, chylous pleural effusions, progressive dyspnea, and extrapulmonary manifestations such as renal angiomyolipomas and lymphangioleiomyomas.

Personalize your experience

Follow Lymphangioleiomyomatosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it